A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

What is pulmonary arterial hypertension and how does Sotatercept help? PAH is a chronic condition that leads to high blood pressure in the arteries and lungs, which makes it harder for the heart to ...

MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by 26th March next year.

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced has approved the medicine sotatercept, Winrevair, to treat pulmonary arterial hypertension. The new ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

To that end, we are immensely proud to be able to present data from preclinical models that provide evidence of a synergistic treatment effect from the combination of seralutinib and sotatercept ...